Achiko Logo cropped.jpg
Achiko’s Position on Omicron Variant
02 déc. 2021 07h30 HE | Achiko AG
The chemical mode of action of AptameX, Achiko's rapid Covid-19 test, strongly suggests that Omicron can be detected as reliably as any other Covid-19 variant known to dateAchiko’s highly effective,...
Achiko Logo cropped.jpg
Achiko’s Covid-19 DNA Aptamer-Based Rapid Testing Platform Update
24 nov. 2021 07h30 HE | Achiko AG
Pilot program in Indonesia is on track with positive results and support for Achiko’s proprietary, low-cost rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service...
Achiko Logo cropped.jpg
Achiko Initiates Development of Dengue Diagnostic Test
05 nov. 2021 07h30 HE | Achiko AG
Achiko to develop dengue fever diagnostic test by applying its DNA aptamer technology platform. This is another promising application of the technology that Achiko is already successfully using to...
Achiko Logo cropped.jpg
Achiko Secures Initial Sales of AptameX Covid-19 Diagnostic Test
27 oct. 2021 07h30 HE | Achiko AG
Achiko has received its first purchase order in Jakarta and Bali in Indonesia.The orders translate to 20,000 tests - while modest in size, the order is expected to pave the way to rapid adoption by...
Achiko Logo cropped.jpg
Market Outlook and Production Plan Update for AptameX
20 oct. 2021 07h30 HE | Achiko AG
After receiving product and registration approval from Indonesia’s Ministry of Health in August, Achiko is positioned to produce up to a million AptameX test kits in Q4 2021, and more if the supply...
Achiko Logo cropped.jpg
Achiko Launches Covid-19 Testing Pilot Program in Indonesia
07 oct. 2021 07h30 HE | Achiko AG
Launch of pilot program in Indonesia for Achiko’s proprietary, low-cost rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service, Teman Sehat (“Health Buddy”).Purpose...
Achiko Logo cropped.jpg
Achiko’s Rapid Covid-19 Diagnostic Test AptameX™ Receives Product and Registration Approval from Indonesia’s Ministry of Health
25 août 2021 07h30 HE | Achiko AG
AptameX™, Achiko’s breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister...
Achiko Logo cropped.jpg
Achiko Engages EpiMetrics to Expand Covid-19 Testing Operations with Udayana University in Bali, Indonesia in the Implementation of a Mass Testing Program
15 juil. 2021 07h30 HE | Achiko AG
ZURICH, Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company...
Achiko Logo cropped.jpg
Achiko Working Towards a Solution for Frequent Global Mass COVID-19 Testing
13 juil. 2021 07h30 HE | Achiko AG
ZURICH, Switzerland, July 13, 2021 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company currently developing technologies that seek to...
Achiko Logo cropped.jpg
Achiko Announces an Extension of its Convertible Loan Transaction with Negma Group
18 juin 2021 12h01 HE | Achiko AG
ZURICH, June 18, 2021 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”) has successfully extended the subordinated convertible loan agreement of CHF 900,000 dated...